Please use this identifier to cite or link to this item:
|Title:||Sugar-lowering drugs for type 2 diabetes mellitus and metabolic syndrome - review of classical and new compounds: Part-I|
Souto, Selma B.
Machado, Ana López
García, Maria Luisa
Silva, Amelia M.
|Publisher:||Multidisciplinary Digital Publishing Institute (MDPI)|
|Citation:||Vieira, Raquel; Souto, Selma B.; Sánchez-López, Elena; Machado, Ana López; Severino, Patricia; Jose, Sajan; Santini, Antonello; Fortuna, Ana; García, Maria Luisa; Silva, Amelia M.; Souto, Eliana, Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic SyndromeReview of Classical and New Compounds: Part-I. Pharmaceuticals, 12(4), 152, 2019|
|Abstract(s):||Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed.|
|Appears in Collections:||CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series|
This item is licensed under a Creative Commons License